AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the ...

The global elahere market is set for rapid growth, projected to surge to $6.07 billion by 2034 at a CAGR of 28.68%. Key ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

Experience healthcare exec Tameeka Smith appointed CEO of CQ fluency, as founder Elisabete Miranda transitions to Board ...

According to a new comprehensive report from The Insight Partners, the global ovarian cancer drugs market is observing ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across multiple tumor types targeting c-Met, with the goal of establishing it as a ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

AbbVie, in partnership with Ironwood Pharmaceuticals, completed a Phase 2 clinical trial of linaclotide for pediatric ...

Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move ...

DelveInsight's BAFF- and APRIL-targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast ...

Acquisitions involving innovator drugs have grown year-on-year with total deal value increasing eight-fold to almost $18 ...